Barclays
CLPT icon

Barclays’s ClearPoint Neuro CLPT Stock Holding History

Barclays’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130K Sell
14,235
-33,078
-70% -$418K ﹤0.01% 3918
2025
Q4 		$647K Buy
47,313
+9,053
+24% +$168K ﹤0.01% 3707
2025
Q3 		$834K Sell
38,260
-9,128
-19% -$108K ﹤0.01% 3479
2025
Q2 		$566K Sell
47,388
-2,528
-5% -$31.8K ﹤0.01% 3697
2025
Q1 		$594K Sell
49,916
-16,520
-25% -$257K ﹤0.01% 3418
2024
Q4 		$1.02M Buy
66,436
+60,762
+1,071% +$787K ﹤0.01% 3368
2024
Q3 		$63.6K Buy
5,674
+1,109
+24% +$10.6K ﹤0.01% 4692
2024
Q2 		$24.6K Sell
4,565
-11,594
-72% -$67.1K ﹤0.01% 4408
2024
Q1 		$110K Sell
16,159
-15,365
-49% -$107K ﹤0.01% 4399
2023
Q4 		$214K Buy
31,524
+27,417
+668% +$155K ﹤0.01% 4388
2023
Q3 		$20.6K Sell
4,107
-487
-11% -$2.9K ﹤0.01% 4175
2023
Q2 		$33.3K Sell
4,594
-7,225
-61% -$61.5K ﹤0.01% 4003
2023
Q1 		$99.8K Sell
11,819
-1,710
-13% -$15K ﹤0.01% 4180
2022
Q4 		$115K Buy
13,529
+12,781
+1,709% +$121K ﹤0.01% 4148
2022
Q3 		$8K Buy
+748
New +$9.86K ﹤0.01% 4381
2022
Q2 		– Sell
-3,093
Closed -$32K – 5051
2022
Q1 		$32K Buy
+3,093
New +$28.2K ﹤0.01% 4285

Other funds holding CLPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Barclays's CLPT Position: Q1 2026 in Review

Barclays reduced its ClearPoint Neuro (CLPT) stake by 70% in Q1 2026, selling an estimated $418K and leaving 14,235 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #3918.

Barclays first reported a position in CLPT in Q1 2022 and has held it in 16 quarters since. The position peaked at $1.02M in Q4 2024. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

  • Barclays held 14,235 shares of ClearPoint Neuro worth $130K as of Q1 2026.
  • Barclays sold 33,078 ClearPoint Neuro shares in Q1 2026, an estimated $418K.
  • ClearPoint Neuro made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3918 holding.
  • Barclays first reported a position in ClearPoint Neuro in Q1 2022 and has held it in 16 quarters since.
  • Barclays's ClearPoint Neuro position peaked at $1.02M in Q4 2024.
  • 118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.